Generate Biomedicines (NASDAQ:GENB) Upgraded at Wall Street Zen

Generate Biomedicines (NASDAQ:GENB) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Several other research firms also recently issued reports on GENB. HC Wainwright upped their target price on Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Morgan Stanley boosted their price target on Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.40.

Generate Biomedicines Stock Performance

NASDAQ:GENB opened at $13.40 on Friday. Generate Biomedicines has a twelve month low of $11.00 and a twelve month high of $18.18. The stock has a market cap of $1.72 billion and a P/E ratio of -12.52. The stock’s 50 day moving average is $14.34.

Generate Biomedicines (NASDAQ:GENB) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.